Maxime RangerPhD, MBA

Chief Executive Officer

Maxime went back to his first love and jumped full-time as giiant’s CEO in 2021, after being General Partner at AmorChem. As a serial entrepreneur, Maxime played a leading role in the creation and management of Mperia therapeutics, Inversago Pharma, SemaThera and Neurasic Therapeutics, to name a few. He is still an active contributor to the Quebec biotech ecosystem through his participation and leadership in Montreal InVivo committees, in addition to being adjunct professor of the Pharmacy School at the University of Montreal.

Maxime played different drug development roles in Montreal biotech companies, namely Ecopia Biosciences (became Thallion Pharma, acquired by Bellus Health), Bioxalis Medica (acquired by Procyon) and Labopharm (acquired by Paladin Labs/Endo). In 2008, he launched his first start-up, Nuvector, where its key asset reached Phase 2 trial with BiolineRx. He followed this in 2011 with the starting-up of gIcare pharma, for which he raised overall $10M from local and European investors. In addition, Maxime spent some time as entrepreneur-in-residence at Univalor, expanding his expertise in technology transfer and licensing. He holds a PhD in Chemistry from Université Laval and performed a postdoctoral fellowship at Stanford University. In addition, he completed a joint Executive MBA at UQAM and Université Paris-Dauphine. Scuba diving and sailing are Maxime’s core passions, and fish meals and sake are source of happiness for him.